The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID, USA). The coordinator of the overall study is Dr Clifton E. Barry, head of the TB research section at NIAID. The PredictTB consortium comprises African, American and European partners.
The clinical trial sites of the EDCTP Predict-TB project are all based in Cape Town, South Africa due to the limited availability of PET/CT in high prevalence areas elsewhere in sub-Saharan Africa. The lead institution is the Immunology Research Group of the University of Stellenbosch, South Africa. Other South African partners include the TASK Foundation NPC, the South African TB Vaccine Initiative (SATVI), the Clinical Infectious Diseases Research Initiative (CIDRI) at the University of Cape Town and the University of Cape Town Lung Institute.
European partners are Leiden University Medical Centre (LUMC) in the Netherlands; Imperial College London, United Kingdom; LINQ management GmbH, Germany; and the European Research and Project Office (EURICE) also in Germany.
* PET/CT = Positron emission tomography/computed tomography
Updated 21 March 2017 regarding the cofunding of the project